Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM)
- PMID: 1374343
Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM)
Abstract
We have examined the effect of the macrocyclic lactone protein kinase C (PK-C) activator bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward normal committed myeloid progenitor cells (day-14 granulocyte-macrophage colony-forming units [CFU-GM]). Preincubation of T-cell- and adherent cell-depleted bone marrow mononuclear cells with 12.5 nM bryostatin 1 and either 1.25 or 50 ng/ml rGM-CSF for 24 h resulted in an 18%-30% survival at 4-5 Gy, whereas cells exposed to rGM-CSF alone gave rise to no detectable colonies at radiation doses greater than 2.5 Gy. Coadministration of bryostatin 1 also led to a threefold increase in Do values for both rGM-CSF concentrations. A similar enhancement of radioprotective effects was observed with the tumor-promoting phorbol ester phorbol dibutyrate. Exposure of cells to both bryostatin 1 and rGM-CSF immediately following irradiation also resulted in enhanced progenitor cell survival when compared to rGM-CSF alone, but radioprotective effects were less than those observed when cells were preincubated with these factors. Cells preconditioned with bryostatin 1 and rGM-CSF prior to exposure to 2 or 4 Gy gave rise to significantly more colonies when radiation was administered as a 4-h divided dose, suggesting that bryostatin 1 may act by potentiating rGM-CSF-induced repair of sublethal radiation damage. Finally, pre-exposure of enriched progenitor cells (CD34+) to bryostatin 1 and rGM-CSF resulted in radioprotective effects that were less than those observed for partially purified populations with respect to the total population of surviving myeloid colonies. However, CD34+ cells preincubated with bryostatin 1 and rGM-CSF prior to irradiation exhibited a significant increase in both the percentage and absolute number of neutrophilic and macrophage colonies, and a reduction in eosinophilic colonies, compared to cells exposed to rGM-CSF alone. These studies suggest that bryostatin 1 (and possibly other PK-C activators) potentiates the in vitro radioprotective effects of rGM-CSF and may also regulate the lineage specificity of this response.
Similar articles
-
Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.Exp Hematol. 1993 Jul;21(7):893-900. Exp Hematol. 1993. PMID: 7686503
-
Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.Leukemia. 1991 May;5(5):392-8. Leukemia. 1991. PMID: 2033960
-
Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.Leukemia. 1992 May;6(5):432-9. Leukemia. 1992. PMID: 1593908
-
Use of flow cytometric CD34 analysis to quantify hematopoietic progenitor cells.Leuk Lymphoma. 1993 Aug;10(6):443-51. doi: 10.3109/10428199309148201. Leuk Lymphoma. 1993. PMID: 7691307 Review.
-
Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression.Drugs. 1992 Apr;43(4):516-60. doi: 10.2165/00003495-199243040-00008. Drugs. 1992. PMID: 1377118 Review.
Cited by
-
Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin.Cancer Chemother Pharmacol. 1994;33(6):509-14. doi: 10.1007/BF00686510. Cancer Chemother Pharmacol. 1994. PMID: 7511065
-
Drug development from marine natural products.Nat Rev Drug Discov. 2009 Jan;8(1):69-85. doi: 10.1038/nrd2487. Epub 2008 Dec 19. Nat Rev Drug Discov. 2009. PMID: 19096380 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical